Publications
- Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study2022 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Telemedicine and inflammatory bowel disease - results of the IBD Assistant pilot project2020 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Tofacitinib induction efficacy and safety in ulcerative colitis at week 8 - results from clinical practice2020 | First Faculty of Medicine
- First clinical experience with biosimilar adalimumab FKB327 in patients with inflammatory bowel disease2020 | First Faculty of Medicine
- Vedolizumab vs. Ustekinumab as second-line therapy in Crohn's disease in clinical practice2019 | First Faculty of Medicine
- Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort2018 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre2017 | First Faculty of Medicine
- Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation2016 | First Faculty of Medicine, Second Faculty of Medicine
- Biosimilar infliximab in anti-TNF-naïve IBD patients - 1-year clinical follow-up2016 | First Faculty of Medicine
- Fecal Calprotectin Levels in Children is more tightly Associated with Histological than with Macroscopic Endoscopy Findings2014 | Second Faculty of Medicine
Loading network view...
